
    
      Safety evaluations included physical examinations, electrocardiograms (ECGs), laboratory
      measures (including plasma concentrations of naltrexone and 6Î²-naltrexol), assessments of
      injection sites, and adverse events (AEs).

      All subjects received psychosocial support at each study visit for the duration of the study,
      with interim telephone contact 2 weeks after each monthly visit.
    
  